Folgen
Keine Story von MC2 Therapeutics mehr verpassen.

MC2 Therapeutics

Filtern
  • 14.09.2022 – 08:01

    MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

    Copenhagen, Denmark (ots/PRNewswire) - - Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated skin diseases - First patients dosed in Europe in Phase 2 trial assessing the safety and efficacy of MC2-25 Cream in Chronic Kidney Disease-associated Pruritus (CKD-aP) stages 3-5 patients - MC2-25 Cream has the potential to become ...

  • 14.09.2022 – 08:01

    MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

    Copenhagen, Denmark (ots/PRNewswire) - - Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated skin diseases - First patients dosed in Europe in Phase 2 trial assessing the safety and efficacy of MC2-25 Cream in Chronic Kidney Disease-associated Pruritus (CKD-aP) stages 3-5 patients - MC2-25 Cream has the potential to become ...

  • 09.06.2022 – 08:01

    Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer

    Copenhagen (ots/PRNewswire) - MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022. Professor Lars Iversen will be a key member of the Executive Team at MC2 ...